Table 2.
Comparison of the sensitivity, specificity, and accuracy of IgM-free AIM, AFP, and DCP for discriminating HCC of all cancer stages
| Marker | Sensitivity (%) | Specificity (%) | Accuracy (%) | |
|---|---|---|---|---|
| Comparison of diagnostic performance for NASH-HCC | ||||
| All cancer stages | IgM-free AIM | 74.1 | 95.3 | 87.1 |
| AFP | 18.5 | 100 | 68.6 | |
| DCP | 40.7 | 90.7 | 71.4 | |
| Comparison of diagnostic performance for HBV-HCC | ||||
| All cancer stages | IgM-free AIM | 37.0 | 94.7 | 60.9 |
| AFP | 33.3 | 84.2 | 54.3 | |
| DCP | 33.3 | 94.7 | 58.7 | |
| Comparison of diagnostic performance for HCV-HCC | ||||
| All cancer stages | IgM-free AIM | 87.8 | 80.0 | 83.3 |
| AFP | 41.5 | 87.3 | 67.7 | |
| DCP | 41.5 | 96.4 | 72.9 | |
| Comparison of diagnostic performance for all HCC patients | ||||
| All cancer stages | IgM-free AIM | 69.5 | 88.0 | 79.7 |
| AFP | 32.6 | 91.5 | 65.1 | |
| DCP | 38.9 | 94.0 | 69.3 | |
The cut-off values of IgM-free AIM, AFP, and DCP were set at 1.6 µg/mL, 20 ng/mL, and 40 mAU/mL, respectively
AFP alpha-fetoprotein, AIM apoptosis inhibitor of macrophage, DCP des-γ-carboxy prothrombin, HBV hepatitis B virus, HCC hepatocellular carcinoma, HCV hepatitis C virus, NASH non-alcoholic steatohepatitis